TD Cowen raised the firm’s price target on Insmed to $67 from $45 and keeps a Buy rating on the shares. The firm said yesterday’s best case scenario ASPEN data drives 80%+ probability of US, EU and Japan approval and they predict clean approval, and model $3.4B in peak sales using a $30K gross price at launch, and 40% peak market share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: